Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.03-063 Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer  Sylvia.

Published byTilde Bendtsen Modified over 5 years ago

Similar presentations

Presentation on theme: "P3.03-063 Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer  Sylvia."— Presentation transcript:

1 P Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer  Sylvia Lee, Aude Chapuis, Thomas Schmitt, Bernardo Goulart, Megan Mcafee, Maurizio Perdicchio, Cecilia Yeung, Hieu Nguyen, Felecia Wagener, Daniel Hunter, Kieu-Thu Bui, Judy Delismon, Natalie Duerkopp, Phil Greenberg  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages S1384-S1385 (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S1384-S1385DOI: (10.1016/j.jtho.2016.11.1962)
Copyright © Terms and Conditions

3 Journal of Thoracic Oncology 2017 12, S1384-S1385DOI: (10.1016/j.jtho.2016.11.1962)
Copyright © Terms and Conditions

Download ppt "P3.03-063 Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer  Sylvia."

Similar presentations

SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
SC09.04 Radiotherapy in China

SC09.04 Radiotherapy in China
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.
Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients  Jean-Louis Pujol, MD, Patrick.

Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients  Jean-Louis Pujol, MD, Patrick.
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis  Hyun Koo.

PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis  Hyun Koo.
P1.08-022 Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.
Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review  Arianna Casagrande, MD, Federica Pederiva,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review  Arianna Casagrande, MD, Federica Pederiva,
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
P2.01-007 Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,
P3.06-003 SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153  David Spigel,

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153  David Spigel,
P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer  Feliciano Barron, Laura-Alejandra.

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer  Feliciano Barron, Laura-Alejandra.

Similar presentations

Ads by Google